Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.

Literature DB >> 15717945

Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.

Abstract

The rapidly expanding knowledge regarding neoplastic diseases is providing a plethora of new targets for drug discovery and development as exemplified by recent data in renal cell carcinoma. The initial experience with molecularly "targeted" agents has demonstrated that development of the newer non-cytotoxic agents will provide unique challenges requiring modification of many traditional drug development concepts and methods. We discuss recently reported data from a few renal cell carcinoma trials with putative cytostatic agents and highlight issues that need to be addressed for efficient development of cytostatic agents during various phases of clinical development.

Entities: Disease

Mesh：

Substances：

Year: 2005 PMID： 15717945 DOI： 10.1007/s11912-005-0037-6

Source DB: PubMed Journal: Curr Oncol Rep ISSN： 1523-3790 Impact factor: 5.075

44 in total

1. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506

2. Hypoxia-inducible expression of tumor-associated carbonic anhydrases.

Authors: C C Wykoff; N J Beasley; P H Watson; K J Turner; J Pastorek; A Sibtain; G D Wilson; H Turley; K L Talks; P H Maxwell; C W Pugh; P J Ratcliffe; A L Harris
Journal: Cancer Res Date: 2000-12-15 Impact factor: 12.701

3. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Authors: Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller
Journal: J Clin Oncol Date: 2005-07-25 Impact factor: 44.544

4. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors: P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal: Nature Date: 1999-05-20 Impact factor: 49.962

Review 5. The von Hippel-Lindau tumor suppressor gene and kidney cancer.

Authors: William G Kaelin
Journal: Clin Cancer Res Date: 2004-09-15 Impact factor: 12.531

6. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.

Authors: Walter M Stadler; Dezheng Huo; Christopher George; Ximing Yang; Christopher W Ryan; Theodore Karrison; Todd M Zimmerman; Nicholas J Vogelzang
Journal: J Urol Date: 2003-10 Impact factor: 7.450

7. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.

Authors: Beverly Drucker; Jennifer Bacik; Michelle Ginsberg; Stephanie Marion; Paul Russo; Madhu Mazumdar; Robert Motzer
Journal: Invest New Drugs Date: 2003-08 Impact factor: 3.850

8. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245

Review 9. Kidney cancer.

Authors: N J Vogelzang; W M Stadler
Journal: Lancet Date: 1998-11-21 Impact factor: 79.321